Lentigen and the University of Pennsylvania Enter License Agreement for Lentiviral Vector Technology
News May 29, 2006
The intellectual property, which was developed at Penn's School of Medicine, has been granted to Lentigen to develop and commercialize products for both research reagents for laboratory research purposes and potentially, therapeutic purposes.
Dr. Boro Dropulic, Founder and CEO of Lentigen, commented, "Lentigen's license agreement with the University of Pennsylvania is part of our goal to continue licensing lentiviral technology from both academic research institutions and the private sector, which we will then work to commercialize."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.